GLP-1 & Incretin Science

What Is the Incretin Effect?

UKPWritten and published by UK Peptides2 min readUpdated 2 cited sources

The short answer

The incretin effect is the observation that glucose taken by mouth triggers substantially more insulin secretion than an identical amount infused intravenously. The difference is caused by gut hormones, principally GLP-1 and GIP, released in response to nutrients reaching the intestine. It accounts for a majority of the insulin response to a meal.

Key facts

Definition
Extra insulin from oral vs IV glucose
Principal hormones
GLP-1 and GIP
GLP-1 source
L cells, distal small intestine and colon
GIP source
K cells, proximal small intestine
Key property
Glucose-dependent insulin release
Native GLP-1 half-life
1-2 minutes
Degrading enzyme
DPP-4

The experiment that defines it

Give a person glucose by mouth and measure the insulin response. Then, on another occasion, infuse glucose intravenously at a rate that reproduces exactly the same blood glucose curve. The insulin response to the oral route is far larger. Since the glucose exposure was identical by construction, something other than glucose must be driving the difference, and that something is hormonal signalling from the gut.

Why the gut signals at all

It is anticipatory. The intestine detects nutrients arriving and signals the pancreas before the resulting glucose has fully entered the circulation. That head start allows insulin secretion to rise in step with absorption rather than lagging behind it. Intravenous glucose bypasses the intestine entirely, so none of that signalling occurs.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Glucose dependence is the safety-critical property

Incretins potentiate insulin secretion only when glucose is elevated. At normal or low glucose they do very little. This is why GLP-1 receptor agonists carry a low intrinsic risk of hypoglycaemia compared with insulin or sulfonylureas, which force insulin release regardless of glucose. It is a property of the physiology the drug class inherited, not something engineered into it.

What goes wrong in type 2 diabetes

The incretin effect is markedly reduced. The GIP arm in particular loses much of its insulinotropic potency, while the GLP-1 arm remains comparatively responsive to pharmacological doses. This asymmetry is a large part of why GLP-1 was pursued as a drug target first, and why the therapeutic role of GIP agonism remained contested long after GLP-1's was settled.

From physiology to pharmacology

Native GLP-1 is destroyed within one to two minutes by DPP-4, so the hormone itself was never usable. Every drug in this class is an attempt to keep GLP-1 receptor signalling going for longer: by blocking the DPP-4 cleavage site, by binding albumin to slow clearance, or by abandoning the peptide entirely for a small molecule the enzyme does not recognise.

Frequently asked questions

How large is the incretin effect?

It accounts for a majority of the insulin response to an oral glucose load in healthy people, which is why bypassing it intravenously produces so much less insulin.

Why do GLP-1 drugs rarely cause hypoglycaemia?

Because incretin signalling is glucose-dependent. It potentiates insulin release when glucose is high and does little when it is not.

Is the incretin effect the same as the drugs' weight effect?

No. The incretin effect describes insulin secretion. Weight reduction comes largely from delayed gastric emptying and central satiety signalling, which are separate consequences of the same receptors.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.